Barclays PLC — Capital/Financing Update 2012

Apr 19, 2012

Final Terms

BARCLAYS BANK PLC

(Incorporated with limited liability in England and Wales)

BARCLAYS CAPITAL (CAYMAN) LIMITED

(Incorporated with limited liability in the Cayman Islands)

GLOBAL STRUCTURED SECURITIES PROGRAMME

for the issue of Securities

BARCLAYS BANK PLC

EUR 5,000,000 Equity Linked Notes due July 2017 (the "Notes")

Series NX00074654

under the Global Structured Securities Programme

The Securities will be publicly offered in Ireland from and including 19 April 2012 to and including 22 June 2012

Issue Price: 100 per cent. of par

This document constitutes the final terms of the Notes (the "Final Terms") described herein for the purposes of Article 5.4 of the Directive 2003/71/EC (the "Prospectus Directive") and is prepared in connection with the Global Structured Securities Programme established by Barclays Bank PLC (the "Bank") and Barclays Capital (Cayman) Limited ("BCCL") and is supplemental to and should be read in conjunction with the Base Prospectus dated 5 August 2011, as supplemented and amended from time to time, which constitutes a base prospectus (the "Base Prospectus") for the purpose of the Prospectus Directive. Full information on the Issuer and the offer of the Securities is only available on the basis of the combination of these Final Terms and the Base Prospectus. The Base Prospectus is available for viewing during normal business hours at the registered office of the Issuer and the specified office of the Issue and Paying Agent for the time being in London and copies may be obtained from such office. Words and expressions defined in the Base Prospectus and not defined in this document shall bear the same meanings when used herein.

The Issuer accepts responsibility for the information contained in these Final Terms. To the best of its knowledge and belief (having taken all reasonable care to ensure that such is the case) the information contained in these Final Terms is in accordance with the facts and does not contain anything likely to affect the import of such information.

Investors should refer to the sections headed "Risk Factors" in the Base Prospectus for a discussion of certain matters that should be considered when making a decision to invest in the Securities.

Final Terms dated 19 April 2012

The distribution of this document and the offer of the Securities in certain jurisdictions may be restricted by law. Persons into whose possession these Final Terms come are required by the Bank to inform themselves about and to observe any such restrictions. Details of selling restrictions for various jurisdictions are set out in "Purchase and Sale" in the Base Prospectus. In particular, the Securities have not been, and will not be, registered under the US Securities Act of 1933, as amended. Trading in the Securities has not been approved by the US Commodity Futures Trading Commission under the US Commodity Exchange Act of 1936, as amended. Subject to certain exceptions, the Securities may not at any time be offered, sold or delivered in the United States or to US persons, nor may any US persons at any time trade or maintain a position in such Securities.

Part A Terms and Conditions of the Securities

The Securities shall have the following terms and conditions, which shall complete, modify and/or amend the Base Conditions and/or any applicable Relevant Annex(es) set out in the Base Prospectus dated 5 August 2011.

Parties
Issuer:	Barclays Bank PLC
Guarantor:	N/A
Manager:	Barclays Bank PLC
Determination Agent:	Barclays Bank PLC
Issue and Paying Agent:	The Bank of New York Mellon
Stabilising Manager:	N/A
Registrar:	N/A
Italian Securities Agent:	N/A
CREST Agent:	N/A
Paying Agents:	N/A
Transfer Agent:	N/A
Exchange Agent:	N/A
Additional Agents:	N/A

THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIES MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, US PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT ("REGULATION S"). THESE FINAL TERMS HAVE BEEN PREPARED BY THE ISSUER FOR USE IN CONNECTION WITH THE OFFER AND SALE OF THE SECURITIES OUTSIDE THE UNITED STATES TO NON-US PERSONS IN RELIANCE ON REGULATION S AND FOR LISTING OF THE SECURITIES ON THE RELEVANT STOCK EXCHANGE, IF ANY, AS STATED HEREIN. FOR A DESCRIPTION OF THESE AND CERTAIN FURTHER RESTRICTIONS ON OFFERS AND SALES OF THE SECURITIES AND DISTRIBUTION OF THESE FINAL TERMS. THE BASE PROSPECTUS AND THE SUPPLEMENTAL PROSPECTUSES SEE "PURCHASE AND SALE" IN THE BASE PROSPECTUS.

Provisions relating to the Securities

1	(i)	Series:	NX00074654
	(ii)	Tranche:	1
2	Currency:		Euro ("EUR")
3	Notes:
	(i)	Aggregate Nominal Amount as at the Issue Date:	EUR 5,000,000
	(ii)	Specified Denomination:	EUR 1,000
	(iii)	Minimum Tradable Amount:	EUR 10,000 and EUR 1,000 thereafter
	(iv)	Calculation Amount as at the	Specified Denomination
		Issue Date:	For the purposes hereof, all references in the Conditions to "Calculation Amount per Security" shall be construed as references to "Calculation Amount" as defined in these Final Terms.
4	Certificates:		N/A
5	Form:
	(i)	Global/Definitive/Uncertificated and dematerialised:	Global Bearer Securities: Permanent Global Security
	(ii)	NGN Form:	Applicable
	(iii)	Held under the NSS:	N/A
	(iv)	CGN Form:	N/A
	(v)	CDI s :	N/A
6	Trade Date:		12 April 2012
7	Issue Date:		6 July 2012
8		Redemption Date:	6 July 2017
9	Issue Price:		100 per cent. of the Aggregate Nominal Amount
10		Relevant Stock Exchange:	London Stock Exchange
11		The following Relevant Annex shall	Equity Linked Annex

Provisions relating to interest (if any) payable on the Securities

12 Interest:	N/A
13 Interest Amount:	N/A
14 Interest Rate:	N/A
15 Screen Rate Determination:	N/A

apply to the Securities:

16	ISDA Determination: N/A
17	Margin:	N/A
18	Minimum/Maximum Interest Rate:	N/A
19	Interest Commencement Date:	N/A
20	Interest Determination Date:	N/A
21	Interest Calculation Periods:	N/A
	long Interest Calculation Periods:
22	Interest Payment Dates:	N/A
23	Day Count Fraction:	N/A
24	Fall back provisions, rounding provisions, denominator and any other terms relating to the method of calculating interest, if different from those set out in the Base Conditions:	N/A
	Provisions relating to Redemption

		25 Settlement Method:	For the purposes of Condition 5.1 of the Base Conditions:
			Cash Settlement
		26 Settlement Currency:	EUR.
27		Settlement Number:	As defined in Condition 24 of the Base Conditions
28	Terms relating to Cash Settled Securities:
	(i)	Final Cash Settlement Amount:	An amount in the Settlement Currency, payable on the Badementian Data in weaport of sock Coloulation

the Redemption Date in respect of each Calculation Amount, calculated as follows:

Calculation Amount x (100% + MAX
$$
(0\%;\sum_{n=1}^{5} \text{Re turn}_n)
$$
)

Where:

"k" represents an integer from 1 to 4.

"MinPerformance_(k)(n)" means in respect of each Observation Date_(n), the four lowest Share, $Perf(n)$ as determined by the Determination Agent on such Observation Date $_{(n)}$ .

"n" represents an Observation Date from 1 to 5.

"Observation Date_(n)" means each date set out in Schedule 2.

"Return_n" is calculated as follows:

$$
\left(\frac{1}{15}x(11x6.20\% + \sum_{k=1}^{4} MinPerformance_{(k)(n)})\right)
$$

			"Share, Perf(n)" is calculated follows: as
			$\frac{Share_i^n -Share_i^{Start}}{Share_i^{Start}}$
			"Share" means in respect of each Share, the
			Share Price of such Share on any Observation Date $(n)$ .
			"Share Start " means in respect of each Share, the
			Share Price of such Share on the Strike Date.
			"Share Price" means, in respect of each Share, the price of such Share at the Valuation Time on any Scheduled Trading Day.
			"Strike Date" means 22 June 2012.
	(ii)	Early Cash Settlement Amount:	As defined in Condition 24 of the Base Conditions
	(iii)	Early Cash Redemption Date:	As defined in Condition 24 of the Base Conditions
29	Securities:	Terms relating to Physically Delivered	N/A
30		Nominal Call Event:	N/A
31	Call Option:		N/A
32	Put Option:		N/A
33		Specified Early Redemption Event:	N/A
34		Maximum and Minimum Redemption Requirements:	N/A
35		Additional Disruption Events in addition to those specified in Condition 24 of the Base Conditions and any applicable Relevant Annex:	N/A
36		Share Linked Securities:	Applicable
	(i)	Shares (each a "Reference Asset"):	A basket of 15 shares (each a "Share" and, collectively, the "Basket"), as set out in Schedule 1
	(ii)	Exchange:	In respect of each Share, as set out in Schedule 1
	(iii)	Related Exchanges:	In respect of each Share, All Exchanges
	(iv)	Exchange Rate:	N/A
	(v)	Weighting for each Reference Asset comprising the Basket of Reference Assets:	N/A
	(vi)	Initial Price of each Reference Asset:	In respect of each Share, the Share Price on the Strike Date

	(vii)	Number of Shares:	N/A
	(viii)	Substitution of Shares:	Substitution of Shares - Standard is applicable
	(ix)	Valuation Date:	Each Observation Date $_{(n)}$
	(x)	Valuation Time:	As defined in the Equity Linked Annex
	(xi)	Averaging:	N/A
	(xii)	Additional Disruption Event in respect of Share Linked Securities:	N/A
	(xiii)	FX Disruption Event:	N/A
	(xiv)	Market Access Dividend and Rights Issue Provisions:	N/A
	(xv)	Dividend Exchange Rate:	N/A
	(xvi)	Other adjustments:	N/A
37		Index Linked Securities:	N/A
38		Inflation Linked Securities:	N/A
39		FX Linked Securities:	N/A
40		Credit Linked Securities:	N/A
41		Commodity Linked Securities:	N/A
42	Index Annex):	(a) Barclays Commodity Index Linked Securities (Section 2 of the Barclays	N/A
	(b) Index Annex):	Barclays Equity Index Linked Securities (Section 3 of the Barclays	N/A
		(c) Barclays FX Index Linked Securities (Section 4 of the Barclays Index Annex):	N/A
	Index Annex):	(d) Barclays Interest Rate Index Linked Securities (Section 5 of the Barclays	N/A
		(e) Barclays Emerging Market Index Linked Securities (Section 6 of the Barclays Index Annex):	N/A
43		Bond Linked Securities:	N/A
44		Fund Linked Securities:	N/A
		Provisions relating to Settlement
45		Settlement in respect of VP Notes, APK	N/A

	Securities:	Registered Securities, Dutch Securities, Swedish Registered Securities, VPS Registered Securities or Spanish
46		Additional provisions relating to Taxes and Settlement Expenses:	N/A
	Definitions
47	Business Day:		As defined in Condition 24 of the Base Conditions
48		Additional Business Centre(s):	N/A
		Selling restrictions and provisions relating to certification
49		Non-US Selling Restrictions:	As described in the Base Prospectus
50		Applicable TEFRA exemption:	Not Applicable
General
51		Business Day Convention:	Modified Following
52		Relevant Clearing Systems:	Euroclear
			Clearstream
53		If syndicated, names of Managers:	N/A
54	(a)	Details relating to Partly Paid Securities:	N/A
	(a)	Details relating to Instalment Notes:	N/A
55		Relevant securities codes:	ISIN: XS0743128372
			Common Code: 074312837
56		Modifications to the Master Subscription Agreement and/or Agency Agreement:	N/A
57	Securities:	Additional Conditions and/or modification to the Conditions of the	For the avoidance of doubt in relation to a delay or postponement of payments and settlement: If the determination of a price or level used to

$to$ calculate any amount payable or deliverable on any payment or settlement date is delayed or postponed pursuant to the terms and conditions of the Securities, payment or settlement will occur on the later of either (i) the scheduled payment or settlement date or (ii) the second Business Day following the date on which such price or level is determined. No additional amounts shall be payable or deliverable by the Issuer because of such postponement.

For the purposes hereof, Base Condition 9.7 shall be modified as follows:

If the date on which any amount is specified as being or is otherwise determined to be, payable in respect of any Security or Coupon is not (i) a Business Day and (ii) in the case of Definitive Securities only, a day other than a Saturday or Sunday on which commercial banks and foreign exchange markets settle payments and are open for general business (including dealing in foreign exchange and foreign Currency deposits) in the relevant place of presentation, then payment will not be made until the next succeeding day which is (i) a Business Day and (ii) in the case of Definitive Securities only, also a day other than a Saturday or Sunday on which commercial banks and foreign exchange markets settle payments and are open for general business (including dealing in foreign exchange and foreign Currency deposits) in the relevant place of presentation, and the holder thereof shall not be entitled to any further payment in respect of such delay.

All references to "Barclays Capital Commodity Index" in the Base Prospectus and in the Conditions shall be construed as references to "Barclays Commodity Index".

All references to "Barclays Capital Equity Index" in the Base Prospectus and in the Conditions shall be construed as references to "Barclays Equity Index".

All references to "Barclays Capital FX Index" in the Base Prospectus and in the Conditions shall be construed as references to "Barclays FX Index".

All references to "Barclays Capital Interest Rate Index" in the Base Prospectus and in the Conditions shall be construed as references to "Barclays Interest Rate Index"

All references to "Barclays Capital Emerging Market Index" in the Base Prospectus and in the Conditions shall be construed as references to "Barclays Emerging Market Index".

All references to "Barclays Capital Index Annex" in the Base Prospectus and in the Conditions shall be construed as references to "Barclays Index Annex".

Part B Other Information

Listing and Admission to Trading $\mathbf{1}$

(i)	Listing:	London
(ii)	Admission to trading:	Application is expected to be made by the Issuer (or on its behalf) for the Securities to be admitted to trading on the London Stock Exchange's Regulated Market.
(iii)	Estimate of total expenses related to admission to trading:	N/A

$\overline{2}$ Ratings

Ratings:

The Securities have not been individually rated.

Notification $\overline{3}$

The Financial Services Authority of the United Kingdom has provided the Central Bank of Ireland with a certificate of approval attesting that the Base Prospectus has been drawn up in accordance with the Prospectus Directive.

$\overline{4}$ Interests of Natural and Legal Persons involved in the Issue

Save as discussed in "Purchase and Sale", so far as the Issuer is aware, no person involved in the offer of the Securities has an interest material to the offer.

$\overline{5}$ Reasons for the Offer, Estimated Net Proceeds and Total Expenses

(i)	Reasons for the offer:	General funding

• $(ii)$ Estimated net proceeds: $N/A$
• $N/A$ $(iii)$ Estimated total expenses:

Fixed Rate Securities Only - Yield $6\phantom{a}$

$N/A$

Floating Rate Securities Only - Historic Interest Rates $\overline{7}$

$N/A$

$\bf 8$ Performance of Reference Asset(s) or Other Variable, Explanation of Effect on Value of Investment and Associated Risks and Other Information Concerning the Reference Asset(s) and/or Other Underlying

Past and further performance (including volatility) of each Share can be obtained on the Bloomberg pages set out in Schedule 1.

Investors should note that historical performance should not be taken as an indication of future performance.

The Issuer does not intend to provide post-issuance information.

$\overline{9}$ Performance of Rate of Exchange and Explanation of Effect on Value of Investment

$N/A$

10 Operational Information

Any clearing system(s) other than Euroclear Bank S.A./N.V. and Clearstream Banking, société anonyme (together with their addresses) and the relevant identification $number(s)$ :	N/A
Delivery:	Delivery free of payment
Names and addresses of additional Paying Agents(s) (if any):	N/A
Intended to be held in a manner which would allow Eurosystem eligibility:	Yes Note that the designation "yes" simply means that the Securities are intended upon issue to be deposited with one of the International Central Securities Depositaries ("ICSDs") as common safekeeper and does not necessarily mean that the Securities will be recognised as eligible collateral for Eurosystem monetary policy and intra-day credit operations by the Eurosystem, either upon issue or at any or all times during their life. Such recognition will depend upon the ECB being satisfied that Eurosystem eligibility criteria have been met.
Offer Information
Offer Price.	Issue Price

The Issue Price includes a commission element to be shared with a third party which shall not exceed 5 per cent. of the Issue Price, further details of which are

$11$

	available upon request.
Conditions to which the offer is subject:	The Issuer reserves the right to withdraw the offer for Securities at any time on or prior to the end of the Offer Period (as defined below). Following withdrawal of the offer, if any application has been made by any potential investor, each such potential investor shall not be entitled to subscribe or otherwise acquire the Securities and any applications will be automatically cancelled and any purchase money will be refunded to the applicant by the Distributor in accordance with the Distributor's usual procedures.
Description of the application process:	An offer of the Securities may be made by the Manager or the Distributor other than pursuant to Article 3(2) of the Prospectus Directive in Ireland (the "Public Offer Jurisdiction") during the period from and including 19 April 2012 to and including 22 June 2012 (the "Offer Period"). Applications for the Securities can be made in the Public Offer Jurisdiction through the Distributor during the Offer Period. The Securities will be placed into the Public Offer Jurisdiction by the Distributor. Distribution will be in accordance with the Distributor's usual procedures, notified to investors
Details of the minimum and/or maximum amount of application:	by the Distributor. The minimum and maximum amount of application from the Distributor will be notified to investors by the Distributor.
possibility to Description of reduce subscriptions and manner for refunding excess amount paid by applicants:	Subscription orders may be reduced in case of oversubscription, excess amount of funds paid being reduced without delay with no entitlement for compensation.
Details of method and time limits for paying up and delivering the Securities:	Investors will be notified by the Distributor of their Securities allocations of and the settlement arrangements in respect thereof.
Manner in and date on which results of the offer are to be made public:	Not Applicable
Procedure for exercise of any right of pre- emption, negotiability of subscription rights and treatment of subscription rights not exercised:	Not Applicable

the Securities are offered and whether tranche(s) have been reserved for certain countries:

Process for notification to applicants of the amount allotted and indication whether dealing may begin before notification is made:

Amount of any expenses and taxes specifically charged to the subscriber or purchaser:

Name(s) and address(es), to the extent known to the Issuer, of the placers in the various countries where the offer takes place:

Categories of prospective investors to which Offers may be made by the Manager or the Distributor in the Public Offer Jurisdiction to any person. Offers (if any) in other EEA countries will only be made by the Manager or the Distributor pursuant to an exemption from the obligation under the Prospectus Directive as implemented in such countries to publish a prospectus.

Each investor will be notified by the Distributor of its allocation of Securities at the time of such investor's application.

No dealings in the Securities may take place prior to the Issue Date.

Not Applicable

Quintas Wealth Management Limited (the "Distributor") Heron House Blackpool Park Blackpool Cork Ireland

Schedule 1

The Basket

i	Stock(i)	Exchange	Bloomberg
			Code
1	Johnson &	New York Stock	JNJ UN Equity
	Iohnson	Exchange
2	Novartis Ag-Reg	Six Swiss Exchange	NOVN VX
			Equity
3	Pfizer Inc	New York Stock	PFE UN Equity
		Exchange
4	Roche Holding	Six Swiss Exchange	ROG VX
	AG-Genusschein		Equity
5	Glaxosmithkline	London Stock	GSK LN Equity
	PLC	Exchange
6	Merck & Co.INC	New York Stock	MRK UN
		Exchange	Equity
7	Sanofi	Euronext	SAN FP Equity
8	Abbott	New York Stock	ABT UN Equity
	Laboratories	Exchange
9	Astrazeneca PLC	New York Stock	AZN LN Equity
		Exchange
10	Amgen INC	Nasdaq	AMGN UQ
			Equity
11	UnitedHealth	New York Stock	UNH UN
	Group PLC	Exchange	Equity
12	Bristol- Myers	New York Stock	BMY UN
	Squibb Co	Exchange	Equity
13	Teva	New York Stock	TEVA UQ
	Pharmaceutical-	Exchange	Equity
	SP ADR
14	ELI LILLY & Co	New York Stock	LLY UN Equity
		Exchange
15	Medtronic Inc	New York Stock	MDT UN
		Exchange	Equity

Schedule 2 Observation Dates

n	Observation Date
	24 June 2013
2	23 June 2014
3	22 June 2015
	22 June 2016
5	22 June 2017